Mizuho began coverage on shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) in a research report issued to clients and investors on Wednesday, The Fly reports. The brokerage set a “buy” rating on the biopharmaceutical company’s stock.

A number of other research firms have also weighed in on AKBA. Royal Bank Of Canada initiated coverage on Akebia Therapeutics in a report on Thursday, September 14th. They set a “sector perform” rating and a $17.00 target price on the stock. ValuEngine raised Akebia Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, September 1st. BidaskClub raised Akebia Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, August 16th. Aegis reaffirmed a “buy” rating on shares of Akebia Therapeutics in a research report on Friday, June 30th. Finally, Zacks Investment Research raised shares of Akebia Therapeutics from a “hold” rating to a “buy” rating and set a $16.00 price objective for the company in a research report on Monday, August 14th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $21.71.

Shares of Akebia Therapeutics (AKBA) traded down 0.52% on Wednesday, hitting $19.23. 297,370 shares of the stock were exchanged. Akebia Therapeutics has a one year low of $7.16 and a one year high of $20.25. The firm’s market capitalization is $351.91 million. The company has a 50-day moving average price of $16.97 and a 200-day moving average price of $13.75.

Akebia Therapeutics (NASDAQ:AKBA) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.36. The business had revenue of $28.52 million during the quarter, compared to the consensus estimate of $26.50 million. Equities research analysts expect that Akebia Therapeutics will post ($2.57) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/04/akebia-therapeutics-inc-akba-earns-buy-rating-from-analysts-at-mizuho.html.

In related news, SVP Michel Dahan sold 5,000 shares of the business’s stock in a transaction on Thursday, September 28th. The stock was sold at an average price of $19.30, for a total value of $96,500.00. Following the completion of the sale, the senior vice president now directly owns 97,224 shares in the company, valued at approximately $1,876,423.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 8.67% of the company’s stock.

Large investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC acquired a new stake in Akebia Therapeutics in the 2nd quarter worth about $132,000. Legal & General Group Plc boosted its holdings in Akebia Therapeutics by 8.0% in the 2nd quarter. Legal & General Group Plc now owns 9,672 shares of the biopharmaceutical company’s stock valued at $142,000 after purchasing an additional 714 shares during the period. Hartwell J M Limited Partnership bought a new stake in Akebia Therapeutics in the 2nd quarter valued at about $144,000. Creative Planning boosted its holdings in Akebia Therapeutics by 2.9% in the 2nd quarter. Creative Planning now owns 10,650 shares of the biopharmaceutical company’s stock valued at $153,000 after purchasing an additional 300 shares during the period. Finally, Cubist Systematic Strategies LLC bought a new stake in Akebia Therapeutics in the 2nd quarter valued at about $159,000. 57.62% of the stock is currently owned by institutional investors and hedge funds.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD).

The Fly

Analyst Recommendations for Akebia Therapeutics (NASDAQ:AKBA)

Receive News & Ratings for Akebia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.